Endocyte
Headquarters
3000 Kent Avenue
West Lafayette
Indiana
47906
United States
171 articles about Endocyte
-
Endocyte Stockholders Approve Merger Agreement with Novartis AG
12/20/2018
Endocyte, Inc. today announced that at its Special Meeting of Stockholders held earlier today, Endocyte’s stockholders approved the adoption of the merger agreement pursuant to which Novartis AG will acquire Endocyte for $24 per share, or a total equity value of approximately $2.1 billion, in cash.
-
Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Endocyte, Inc. In The U.S. District Court For The Southern District Of New York
11/16/2018
Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court for the Southern District of New York, Case No. 1:18-cv-10392-JMF, on behalf of public common shareholders of Endocyte, Inc who held Endocyte securities on the record date November 15, 2018
-
Days after Novartis axed one-fifth of its research programs, the Swiss pharma giant said it intends to seek regulatory approval for 60 new treatments between 2019 and 2021.
-
Shares of Indiana-based Endocyte have shot up more than 50 percent in pre-market trading after Swiss pharma giant Novartis announced it was acquiring the company for $2.1 billion in cash. The deal will allow the company to expand its radiopharmaceuticals business.
-
Amidst Strong Quarterly Growth, Novartis Receives FDA Complete Response Letter for Canakinumab
10/18/2018
Buried deep in an announcement touting a 6 percent growth in net sales driven by strong revenue gains of Cosentyx, Swiss pharma giant Novartis reported it received a Complete Response Letter from the U.S. Food and Drug Administration for canakinumab as a potential treatment for cardiovascular ris... -
Shares of Indiana-based Endocyte have slipped more than 3 percent this morning after the company announced the U.S. Food and Drug Administration accepted radiographic progression-free survival as an alternative primary endpoint in its Phase III VISION trial.
-
Endocyte and ITM Announce Long-Term Supply Agreement for No-Carrier-Added Lutetium-177
7/9/2018
Strategic Partnership supports Commercialization beyond ongoing Phase 3 VISION Trial of 177Lu-PSMA-617
-
Endocyte Reports Third Quarter Financial Results
11/7/2017
A conference call will be held today at 4:30 p.m. EST.
-
Endocyte Announces Third Quarter 2017 Earnings Conference Call
10/31/2017
The company will host a conference call on Monday, Nov. 6th, at 4:30 p.m. EST to discuss the results.
-
Troubled Endocyte Inks $172 Million Prostate Cancer Pact
10/2/2017
-
Endocyte Reports Second Quarter Financial Results And Provides Clinical And Pipeline Update
8/9/2017
-
Endocyte Announces Second Quarter 2017 Earnings Conference Call
8/2/2017
-
Stock Tanks as Endocyte Cuts 40% of Workforce, Slashes 2 Clinical Programs
6/5/2017
-
Endocyte Reports First Quarter Financial Results And Provides Clinical And Pipeline Update
5/10/2017
-
Endocyte Reports Fourth Quarter And Year End 2016 Financial Results And Provides Clinical And Pipeline Update
3/13/2017
-
Endocyte And Seattle Children's Research Institute To Collaborate On Endocyte’s Small Molecule Drug Conjugate Bi-Specific Adaptor Molecules For CAR T-Cell Therapies
3/10/2017
-
Endocyte Announces Fourth Quarter And Full Year 2016 Earnings Conference Call
3/2/2017
-
Endocyte Appoints Michael T. Andriole As Chief Financial Officer
2/21/2017
-
Endocyte Reports Third Quarter 2016 Financial Results
11/10/2016
-
Endocyte Announces Third Quarter 2016 Earnings Conference Call
11/3/2016